Press release

Luebeck, August 9th, 2017

EUROIMMUN is pleased to announce that European Patent EP2514837 has been revoked in its entirety in opposition proceedings by the European Patent Office in their decision dated July 7, 2017.

The claims of the patent as granted relate to a method for detecting brain damage caused by Alzheimer’s disease using an immunoassay, wherein an enhanced presence of neurogranin indicates an increased probability of brain damage caused by Alzheimer’s Disease in a patient.

The European Patent Office agreed with EUROIMMUN, who had lodged the opposition, and a second opponent that the claims as granted do not meet the patentability requirements according to the European Patent Convention.

The decision may be appealed by the owner of the patent.

EUROIMMUN has an extensive IP portfolio comprising more than 450 proprietary and licensed-in IP rights.